Présentation de l'entreprise
Trevi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of investigational therapies designed to treat chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, a classification that signifies its focus on innovative medical products and advanced therapeutic interventions rather than mature consumer goods. Trevi Therapeutics, Inc. currently holds a market capitalization of $1.68B and employs a workforce of 34 individuals, reflecting its status as a mid-to-small cap enterprise with a specialized focus. The combination of a $1.68B market cap and a relatively small employee base of 34 suggests that the company's valuation is heavily driven by the potential of its clinical pipeline and intellectual property rather than established revenue streams or mass-market scale operations typical of large-cap pharmaceutical firms.
Santé financière
The financial statements for Trevi Therapeutics, Inc. reveal a net income of $-42,759,000 and an EBITDA of $-49,184,000, while annual revenue data is not available for the trailing twelve months. The significant gap between the reported net income of $-42,759,000 and the EBITDA of $-49,184,000 indicates substantial non-operating expenses or interest costs that are impacting the bottom line, alongside the absence of revenue figures which points to the company being in a pre-commercialization phase where research and development expenditures dominate the cost structure. The company reports a free cash flow of $-27,859,000, a metric that underscores a consumption of cash necessary to fund ongoing clinical trials and operational expenses, thereby limiting immediate financial flexibility for external acquisitions or dividend distributions. Analysis of the margin structure shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, levels that are characteristic of early-stage biotechnology firms that have not yet achieved commercial product sales or profitability. Regarding liquidity and leverage, Trevi Therapeutics, Inc. maintains a cash position of $188.26M against total debt of $753,000, resulting in a debt-to-equity ratio of 0.41, which illustrates a balance sheet that is highly conservative with minimal leverage relative to its asset base. The current ratio stands at 19.66, a figure that indicates an exceptionally strong ability to meet short-term obligations with liquid assets, providing a robust buffer against unforeseen liquidity needs. Furthermore, the return on equity is reported at -30.2% and the return on assets at -20.3%, metrics that reflect the temporary nature of negative returns typical for companies in the research and development stage where capital is deployed to generate future value rather than current profits.
Évaluation de la valorisation
Valuation multiples for Trevi Therapeutics, Inc. include a P/E ratio (TTM) that is not available due to lack of earnings, a forward P/E of -23.13, and an EV/EBITDA of -30.31. The negative forward P/E and negative EV/EBITDA ratios are direct mathematical consequences of the company's reported losses, implying that traditional earnings-based valuation models are currently inapplicable and that the market is pricing the stock based on future potential rather than current profitability. The price-to-book ratio is 9.15, a figure that indicates a significant market premium over the company's book value, suggesting that investors are willing to pay a high multiple for the intangible assets and clinical pipeline associated with the biotechnology sector. Since revenue data is unavailable, the price-to-sales ratio is not applicable, and the negative EV/EBITDA further confirms that the company is being valued on a speculative basis common for clinical-stage assets. The stock has traded within a 52-week range with a high of $14.39 and a low of $4.85, meaning the current price sits somewhere within this volatility band, reflecting the high-risk nature of the investment. The beta value is 1.00, which indicates that the stock's price volatility generally moves in tandem with the broader market, offering no significant downside protection or upside acceleration relative to the overall index during market fluctuations.
Growth & Income
The company reports revenue growth (YoY) as not available and earnings growth (YoY) as not available, as the lack of historical revenue data precludes the calculation of year-over-year growth rates for a clinical-stage entity. In the absence of positive earnings growth figures or established revenue, the concept of earnings growing faster or slower than revenue is not applicable to the current operational stage of Trevi Therapeutics, Inc. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the firm reinvests all available capital and future projected earnings back into research and development activities rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a complete focus on capital deployment for clinical advancement and product development, with no current income generation for shareholders.